NCT01169298 - A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2010

Primary Completion Date

December 1, 2013

Study Completion Date

December 20, 2013

Conditions

Adult T-cell Leukemia-LymphomaPeripheral T-cell Lymphoma

Interventions

DRUG

Lenalidomide

Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)

Trial Locations (6)

811-1395

National Kyusyu Cancer Center, Fukuoka

890-0064

Imamura Bun-in Hospital, Kagoshima

860-8556

Kumamoto University Hospital, Kumamoto

852-8501

Nagasaki University Hospital, Nagasaki

466-8650

Nagoya Daini Red Cross Hospital, Nagoya

104-0045

National Cancer Center Hospital, Tokyo